Wave Life Sciences .(US:WVE) Xin Lang Cai Jing·2025-12-08 14:56Core Viewpoint - Wave Life Sciences' stock surged nearly 80% to a new yearly high of $13.42 following positive mid-stage trial results for its obesity treatment WVE-007, showing promising weight loss effects without muscle loss [1] Group 1: Clinical Trial Results - The mid-stage trial data for WVE-007 indicated improvements in body composition, with a single 240 mg dose resulting in a 9.4% reduction in visceral fat and a 4.5% reduction in total body fat, alongside a 3.2% increase in lean body mass [1] - The treatment demonstrated a weight loss effect comparable to GLP-1 therapies, but without associated muscle loss [1] Group 2: Safety and Future Updates - Wave Life Sciences reported that WVE-007 was overall safe and well-tolerated, with only mild treatment-related adverse events observed [1] - The company anticipates releasing further clinical data updates in the first quarter of 2026, which will include six-month follow-up data for the 240 mg single-dose group [1]